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Introduction 
Models of disease 
Induced pluripotent stem cells (iPSCs) are pluripotent stem cells that can 
be obtained from somatic cells by the addition of four transcription 
factors: Oct4, Sox2, Klf4, C-Myc. As pluripotent stem cells, iPSC can 
differentiate into any cell type of the human body. 
Therefore, iPSC technology allows for the generation of any adult cell type 
from a somatic cell. 
Cell Therapy 
Materials and Methods 
Results 
Conclusions 
 
 The use of iPSC-derived cells as in vitro models of disease has allowed the elucidation of a lot of abnormal pathways  
        and molecular alterations in ALS, PD, HD and AD. Furthermore, it has been  an useful tool to test the efficacy of 
        innovative treatments. It is the only feasible application of iPSCs in humans currently. 
 
 Regarding the use of the iPSC technology in cell therapy some approaches have been developed and have shown promising results.  
        However, there is still a lot of work ahead until this application can be performed in human patients.  
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Disease Phenotype in iPSC-Derived Progeny 
AD     Amyloid β (Aβ) secretion  
    Tau phosphorylation 
Active glycogen synthase kinase 3 (GSK3) 
ALS Reduced levels and lack of inclusions of the vamp associated protein B 
(VAPB) 
HD    Lysosomal activity 
Susceptibility to stress which increases cell death 
   TGFβ and N-cadherin  
PD    Sensitivity to oxidative stress 
Presence of α-synuclein bodies  
Impaired mitochondrial function and autophagy pathways  
GSK3 phosphorylates 
tau when activated by 
Aβ oligomers 
Figure 3: Abnormal and altered 
pathways seen in iPSC-derived 
progeny from patients with HD 
(A), PD (B) and AD (C) that lead 
to the apoptosis of neurons (*) 
AD 
•  γ-secretase inhibitors 
•  β-secretase inhibitors 
•  Docosahexaenoic acid (DHA)  
PD 
 
• ERK inhibitors 
• LRRK2 inhibitors 
 
HD 
 
• Genetic correction of the huntingtin gene by homologous 
recombination 
 
The following treatments and drugs have been tested in iPSC-derived 
neurons from patients of AD, HD and PD and have shown promising results:  
The aim of this project is to review new findings and approaches, allowed by 
iPSC technology, that may be useful to treat neurodegenerative diseases.  
In order to get a broad and accurate view four of the most relevant illnesses 
were studied, for which an overview of symptoms and causes is listed below: 
Disease Genetic defect Symptoms and Causes 
Alzheimer 
disease (AD)  
Multifactorial or APP, 
PS1 or PS2 mutations 
Progressive memory loss and cognitive 
disturbance  
Caused by the loss of cholinergic neurons 
in the hippocampus 
Amyotrophic 
lateral 
sclerosis 
(ALS) 
Multifactorial or SOD1, 
VAPB mutations   
Weakness and paralysis  
Caused by the loss of motor neurons and 
neuromuscular degeneration 
Huntington’s 
disease (HD) 
CAG repeat expansion in 
the huntingtin gene  
Progressive chorea and dementia  
Caused by the loss of neurons in striatum 
and cortex 
Parkinson’s 
disease (PD) 
Multifactorial or LRRK2, 
PINK1, PARKIN, SNCA 
mutations 
Coordination difficulties,  stiffness, tremor 
of hands…  
Caused by the loss of dopaminergic 
neurons  in the substantia nigra, pars 
compacta  
 
 
Disease 
Cell Therapy With iPSC-derived neurons or NPC 
iPSC from animal 
models  
iPSC from human healthy 
donors  
iPSC from human 
patients 
 
 
 
ALS 
- Moderated amelioration of 
the disease pathology due to 
the production of VEGF and 
AKT activation 
 
Motor function and life span 
significantly improved due to 
an increased production of 
neurotrophic factors and a  
reduction in the immune 
response 
- 
 
 
HD 
- - Improvement of the 
pathology 
Recapitulation of 
the disease long 
term post 
engraftment 
 
PD 
Improvement in the 
motor behaviour  
Teratoma formation 
rescued 
Not statistically 
representative motor 
recovery and formation of 
teratomas 
Improvement of 
behavioural and 
motor impairments 
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Neurons obtained through the iPSC technology from PD patient’s 
fibroblasts were engrafted in the striatum of the PD rat model and 
improved its altered behaviour. Therefore, neurons obtained from 
patient somatic cells could be useful to treat their own disease. 
Biopsy extraction  
from a PD patient 
Reprogramming  
into iPSC 
Differentiation into  
dopaminergic neurons 
Engraftment in a rat  
model of PD 
Models Of Disease Cell Therapy 
The iPSC technology allows for 
the generation of neurons from 
somatic cells of patients who 
suffer from neurodegenerative 
diseases.  
The neurons yielded from 
patients recapitulate the disease 
phenotype and can be used as in 
vitro human models of disease, 
which have two main 
applications: 
 
 Understanding the molecular 
basis of neurodegenerative 
diseases, still fairly unknown. 
 Seek for new targets of 
treatments and drug testing. 
The neuron loss is the most 
characteristic feature of 
neurodegenerative diseases. As 
previously mentioned, iPSC have the 
potential of generating neurons, which 
could be engrafted in the loss sites of 
patients in order to perform 
regenerative medicine.  
 The main goal is the cell therapy 
with neurons or neural precursors 
obtained from patient somatic 
cells through the iPSC technology 
to carry out an autologous 
transplantation (lack of 
engraftment rejection). 
 However, the possibility of 
teratoma formation or disease 
recapitulation hinder the use of 
this approach in humans. 
 
Figure 1: 
generation of 
iPSC (1) 
The generation of neurons from patient somatic cells through the iPSC 
technology has allowed the discovery of molecular alterations that lead to 
cell death in AD, ALS, HD and PD; compiled in the following table and 
schematic representations: 
Studies in which neurons or neural precursor cells (NPC) from animals’, human 
donor’s and patient’s somatic cells (obtained through the iPSC technology) 
were engrafted in mice and rat models of ALS, HD and PD showed the 
following results: 
 
Search on PubMed database: scientific literature including published 
reviews and papers.  
 
Selection of literature: by journal  relevance, citations in later papers and 
publication date (most of the literature was published in the past 5 years).  
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(*)     Figures created by the author 
 
Prevent the formation of 
α-syn aggregates and 
oxidative stress 
Prevent the formation 
of Aβ oligomers 
Figure 4:     Reduced motor 
asymmetry of PD rat models 
after transplantation of 
differentiated PD-iPS cells (2) 
Figure 2: Applications of iPSCs obtained from patient’s fibroblasts in the treatment 
of neurodegenerative diseases (*) 
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